ATXS
Price
$7.30
Change
+$0.15 (+2.10%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
411.97M
46 days until earnings call
KNSA
Price
$36.49
Change
+$0.98 (+2.76%)
Updated
Sep 26 closing price
Capitalization
2.7B
38 days until earnings call
Interact to see
Advertisement

ATXS vs KNSA

Header iconATXS vs KNSA Comparison
Open Charts ATXS vs KNSABanner chart's image
Astria Therapeutics
Price$7.30
Change+$0.15 (+2.10%)
Volume$3.97K
Capitalization411.97M
Kiniksa Pharmaceuticals International
Price$36.49
Change+$0.98 (+2.76%)
Volume$285.3K
Capitalization2.7B
ATXS vs KNSA Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. KNSA commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and KNSA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ATXS: $7.30 vs. KNSA: $36.51)
Brand notoriety: ATXS and KNSA are both not notable
ATXS represents the Biotechnology, while KNSA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ATXS: 35% vs. KNSA: 18%
Market capitalization -- ATXS: $403.51M vs. KNSA: $2.63B
ATXS [@Biotechnology] is valued at $403.51M. KNSA’s [@Pharmaceuticals: Generic] market capitalization is $2.63B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.91B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileKNSA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • KNSA’s FA Score: 1 green, 4 red.
According to our system of comparison, KNSA is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 3 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 6 bearish.
  • KNSA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both ATXS and KNSA are a bad buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а +3.55% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +3.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.97%. For the same industry, the average monthly price growth was +24.39%, and the average quarterly price growth was +67.10%.

Reported Earning Dates

ATXS is expected to report earnings on Nov 12, 2025.

KNSA is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-0.97% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNSA($2.7B) has a higher market cap than ATXS($412M). KNSA YTD gains are higher at: 84.479 vs. ATXS (-18.345). KNSA has higher annual earnings (EBITDA): 5.98M vs. ATXS (-131.42M). KNSA has more cash in the bank: 308M vs. ATXS (259M). ATXS has less debt than KNSA: ATXS (4.77M) vs KNSA (9.77M). KNSA has higher revenues than ATXS: KNSA (529M) vs ATXS (0).
ATXSKNSAATXS / KNSA
Capitalization412M2.7B15%
EBITDA-131.42M5.98M-2,199%
Gain YTD-18.34584.479-22%
P/E RatioN/A729.80-
Revenue0529M-
Total Cash259M308M84%
Total Debt4.77M9.77M49%
FUNDAMENTALS RATINGS
ATXS vs KNSA: Fundamental Ratings
ATXS
KNSA
OUTLOOK RATING
1..100
6977
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
97
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
9891
PRICE GROWTH RATING
1..100
4540
P/E GROWTH RATING
1..100
10029
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (55) in the Biotechnology industry is somewhat better than the same rating for KNSA (97) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew somewhat faster than KNSA’s over the last 12 months.

KNSA's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for ATXS (100) in the Biotechnology industry. This means that KNSA’s stock grew somewhat faster than ATXS’s over the last 12 months.

KNSA's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as ATXS (98) in the Biotechnology industry. This means that KNSA’s stock grew similarly to ATXS’s over the last 12 months.

KNSA's Price Growth Rating (40) in the Pharmaceuticals Major industry is in the same range as ATXS (45) in the Biotechnology industry. This means that KNSA’s stock grew similarly to ATXS’s over the last 12 months.

KNSA's P/E Growth Rating (29) in the Pharmaceuticals Major industry is significantly better than the same rating for ATXS (100) in the Biotechnology industry. This means that KNSA’s stock grew significantly faster than ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSKNSA
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KNSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RIVCX13.340.14
+1.06%
Victory RS Investors C
ARIMX10.270.10
+0.98%
AMG River Road Small-Mid Cap Value I
WHGAX20.760.19
+0.92%
Westwood Quality SmallCap Fund A
JSLNX20.980.10
+0.48%
Janus Henderson Global Select N
AULDX111.020.37
+0.33%
American Century Ultra® R6

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with CRNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+2.10%
CRNX - ATXS
53%
Loosely correlated
+27.92%
DNLI - ATXS
51%
Loosely correlated
+3.87%
XENE - ATXS
51%
Loosely correlated
+4.00%
VRDN - ATXS
51%
Loosely correlated
+5.77%
NRIX - ATXS
50%
Loosely correlated
+7.20%
More

KNSA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNSA
1D Price
Change %
KNSA100%
+2.76%
COYA - KNSA
39%
Loosely correlated
+3.39%
JBIO - KNSA
37%
Loosely correlated
+5.21%
SNDX - KNSA
36%
Loosely correlated
+4.32%
CPRX - KNSA
35%
Loosely correlated
+2.04%
ATXS - KNSA
35%
Loosely correlated
+2.10%
More